Background: Although immune checkpoint inhibitors (ICIs) have provided practice-changing outcomes in treating many cancers, ICI-related gastrointestinal toxicity can limit their use. Upper gastrointestinal toxicity is not common nor as well described as lower gastrointestinal toxicity. We aimed to characterize the clinical presentation, endoscopic and histologic features, treatment response, and outcomes of ICI-related esophagitis. Methods: We retrospectively studied patients at The University of Texas MD Anderson Cancer Center in whom esophagitis developed after receiving ICIs from June 2011 through January 2020. We included patients with endoscopic evidence of esophagitis and excluded those with other obvious causes of esophagitis. A chi-square test was used to assess associations between categorical variables. The Mann-Whitney U test was used to compare differences between continuous variables. Results: Of 657 consecutive patients who underwent esophagogastroduodenoscopy (EGD) during or within 6 months of completing ICI-based therapy, 21 (3%) had esophagitis deemed to be from ICIs. Of these patients, 1 (5%) received an inhibitor of CTLA-4 alone, 15 (71%) received anti–PD-1 or PD-L1 monotherapy, and 5 (24%) received a combination of these. Median time from ICI initiation to onset of esophagitis was 4 months. Upon evaluation with EGD, only 3 patients (14%) had isolated esophageal involvement; 18 (86%) had concurrent involvement of the stomach, duodenum, or both. Most patients (67%) were treated with proton pump inhibitors, and 4 (19%) received steroids (prednisone or budesonide). The mortality rate was 38% (median follow-up, 15 months). Conclusions: Esophagitis associated with ICI use is rare. The diagnosis is one of exclusion because its clinical presentation appears similar to that of inflammation resulting from other causes. It often occurs in conjunction with other upper gastrointestinal toxicity. Symptoms are mild and respond well to nonimmunosuppressive treatment, with few severe complications.
Submitted September 5, 2020; final revision received October 18, 2020; accepted for publication October 20, 2020. Published online June 11, 2021.
Author contributions:Study concept and design: Thomas, Wang. Data acquisition: Panneerselvan, Lum. Data analysis and interpretation: Panneerselvan, Thomas, Wang. Manuscript preparation: Panneerselvam, Thomas, Wang. Critical revision: Amin, Zhang, Richards, Altan, Grivas, Thompson, Thomas, Wang. Pathology slide review and histologic images: Wei, Tan.
Disclosures: Dr. Grivas has disclosed serving as a consultant or in an advisory role for AstraZeneca, Bayer, Bristol Myers Squibb, Clovis Oncology, Dyania Health, Driver, EMD Serono, Exelixis, Foundation Medicine, Genentech/Roche, Genzyme, GlaxoSmithKline, Heron Therapeutics, Immunomedics, Infinity Pharmaceuticals, Janssen, Merck & Co., Mirati Therapeutics, Pfizer, QED Therapeutics, and Seattle Genetics; and receiving research support from Bavarian Nordic, Bristol Myers Squibb, Clovis Oncology, Debiopharm, GlaxoSmithKline, Immunomedics, Kure It Cancer Research, Merck & Co., Mirati Therapeutics, Pfizer, and QED Therapeutics. Dr. Thompson has disclosed receiving grant/research support from Merck, Hoffmann-LaRoche, Pfizer, Five Prime, Novartis, Incyte, Trillium, and Xencor; and serving as a consultant for Neoleukin, Aveo, and Regeneron. Dr. Wang has disclosed serving as a consultant for Tillotts Pharma. The remaining authors have disclosed that they have not received any financial consideration from any person or organization to support the preparation, analysis, results, or discussion of this article.
Correspondence: Yinghong Wang, MD, PhD, Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Unit 1466, 1515 Holcombe Boulevard, Houston, TX 77030. Email: firstname.lastname@example.org
PuzanovI, DiabA, AbdallahK,
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer2017;5:95.
PuzanovI, DiabA, AbdallahK, Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017;5:95.10.1186/s40425-017-0300-z)| false
KumarV, ChaudharyN, GargM, Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol 2017;8:49.10.3389/fphar.2017.0004928228726)| false
HodiFS, PostowMA, ChesneyJA,
Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study [abstract]. J Clin Oncol2015; 33(Suppl):Abstract 9004.
TangT, Abu-SbeihH, LuoW,
Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. Scand J Gastroenterol2019;54:538–545.
GonzalezRS, SalariaSN, BohannonCD, PD-1 inhibitor gastroenterocolitis: case series and appraisal of ‘immunomodulatory gastroenterocolitis’. Histopathology 2017;70:558–567.10.1111/his.1311828000302)| false
BeckKE, BlansfieldJA, TranKQ, Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24:2283–2289.10.1200/JCO.2005.04.571616710025)| false
Acero BrandFZ, SuterN, AdamJP, Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab. J Immunother Cancer 2018;6:22.10.1186/s40425-018-0332-z)| false
HorisbergerA, La RosaS, ZurcherJP, A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy. J Immunother Cancer 2018;6:156.3058722710.1186/s40425-018-0481-0)| false
NihoS, YoshidaT, AkimotoT,
Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study. Lung Cancer2020;141:64–71.
NihoS, YoshidaT, AkimotoT, Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study. Lung Cancer 2020;141:64–71.10.1016/j.lungcan.2020.01.00831955002)| false
LiuQ, XiaY, ChenY,
A study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin for advanced esophageal squamous cell carcinoma with T4 and/or M1 lymph node metastasis or locoregional recurrence. Radiat Oncol2020;15:75.
LiuQ, XiaY, ChenY, A study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin for advanced esophageal squamous cell carcinoma with T4 and/or M1 lymph node metastasis or locoregional recurrence. Radiat Oncol 2020;15:75.3226892510.1186/s13014-020-01518-2)| false
SchadendorfD, WolchokJD, HodiFS,
Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol2017;35:3807–3814.
SchadendorfD, WolchokJD, HodiFS, Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol 2017;35:3807–3814.2884138710.1200/JCO.2017.73.2289)| false
BertrandA, KostineM, BarnetcheT, Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med 2015;13:211.10.1186/s12916-015-0455-826337719)| false
KhojaL, DayD, Wei-Wu ChenT, Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol 2017;28:2377–2385.10.1093/annonc/mdx28628945858)| false
HorvatTZ, AdelNG, DangTO,
Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol2015;33:3193–3198.
HorvatTZ, AdelNG, DangTO, Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 2015;33:3193–3198.10.1200/JCO.2015.60.844826282644)| false
ZhuAX, FinnRS, EdelineJ,
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol2018;19:940–952.
IwamaS, De RemigisA, CallahanMK, Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med 2014;6:230ra45.2469568510.1126/scitranslmed.3008002)| false
WeberJS, DummerR, de PrilV,
Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer2013;119:1675–1682.
WeberJS, DummerR, de PrilV, Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 2013;119:1675–1682.2340056410.1002/cncr.27969)| false